Besides, the cumulative risk of developing breast cancer by the age of 70 is approximately 37.9% in BRCA1 mutation carriers and 36.5% in BRCA2 mutation carriers in China, corresponding to a 10-fold increase compared with the general population (Yao et al., 2016), which indicated that it is necessary to have BRCA1/2 testing for Chinese breast cancer patients. The gene discussed is BRCA1; the disease is breast carcinoma.